Ann Surg Oncol (2018) 25:1896–1903 https://doi.org/10.1245/s10434-018-6512-8 OR IG INA L A R TIC L E – PA NC REATIC TU MO RS FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma 1 2 3 4 5 Mashaal Dhir, MD , Mazen S. Zenati, MD, PhD , Ahmad Hamad, MD , Aatur D. Singhi, MD , Nathan Bahary, MD , 3 3 3,6 Melissa E. Hogg, MD , Herbert J. Zeh III, MD , and Amer H. Zureikat, MD, FACS 1 2 Department of Surgery, SUNY Upstate Medical University, Syracuse, NY; Department of Biostatistics and Epidemiology, University of Pittsburgh, Pittsburgh, PA; Department of Surgery, University of Pittsburgh Medical Center, 4 5 Pittsburgh, PA; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; Department of Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA; Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA ABSTRACT two regimens were equally effective in achieving an 80% Background. Both FOLFIRINOX and gemcitabine/nab- decline in CA19-9 (p = 0.8). The R0 resection rates were paclitaxel (G-nP) are used increasingly in the neoadjuvant similar (80%), but FOLFIRINOX was associated with a treatment (NAT) of pancreatic ductal adenocarcinoma reduction in
Annals of Surgical Oncology – Springer Journals
Published: May 14, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera